Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Unresectable Melanoma · Metastatic Cutaneous Melanoma · Metastatic Uveal Melanoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Contact: Study coordinator (Zhen J Peng, Phd) · Zhen-Peng@beijing-biotech.com · +86 13076790039

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

Melanoma · Clear-Cell Renal-Cell Carcinoma (ccRCC) · Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Los Angeles, United States · San Francisco, United States

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma · Unresectable Melanoma

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · Boston, United States

A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy

Melanoma

Abroad (travel likely)RecruitingPHASE2

Hefei, China · Beijing, China

A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

Melanoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China